Rare diseases
Investigational molecules
Locations
Via Mauro Gavazzeni 21, 24125 Bergamo, Italy
Cliniche Gavazzeni S.p.A. in Bergamo, Italy specialises in clinical trials of conditions such as Non-small cell lung cancer, Atrial fibrillation, Hormone receptor positive breast cancer, Prostate cancer, and other specialisations. This site conducts important research.
The Medical Oncology department at Cliniche Gavazzeni is conducting studies that address acute coronary syndrome and aim to lower the risk of repeat heart attacks, while separate trials evaluate new oral anticoagulants for patients with atrial fibrillation. Additional research explores therapies designed to cut major adverse cardiovascular events in individuals with a history of myocardial infarction.
These investigations are part of the site’s broader effort to improve heart health outcomes for the Bergamo community and beyond.
A robust portfolio of oncology trials at Cliniche Gavazzeni targets advanced solid tumors, with a focus on hormone‑responsive breast cancer, various forms of lung cancer, and rare lymphomas. The studies compare innovative antibody‑drug conjugates and cellular therapies against standard chemotherapy to extend survival and enhance response rates.
By testing novel agents, the site contributes to advancing cancer care across multiple disease subtypes.
The clinic’s metabolic research includes a trial of a peptide‑based therapy aimed at improving cardiovascular safety in patients with obesity. Participants receive the investigational drug to assess its impact on weight reduction and related metabolic parameters, with the goal of lowering heart‑related complications.
These efforts align with broader public‑health strategies to combat the growing burden of metabolic disease in Italy.
Beyond individual disease trials, Cliniche Gavazzeni engages in research that examines how environmental exposures influence cancer incidence and cardiovascular risk. Studies also evaluate community‑based screening programs and health‑care delivery models to improve early detection and treatment accessibility.
This multidisciplinary approach supports the institution’s commitment to population health and preventive medicine.
Clinical trials currently enrolling participants at this site.
Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction
ItalyA Study of Setidegrasib with Chemotherapy Drug Combination as First‑Line Treatment in Adults with KRAS G12D‑mutated Metastatic Pancreatic Cancer
ItalyAdjuvant Therapy with RO7435846 (divarasib) versus Pembrolizumab or Nivolumab or Observation in Patients After Surgery for Stage II‑III KRAS G12C NSCLC
ItalyA Study of ABBV-706 to Assess Safety and Efficacy Compared with Standard Drug Combination in Adults with Relapsed or Refractory Small Cell Lung Cancer
ItalyPhase 2 Study of PF-08634404 with Carboplatin and Etoposide in Adults with Untreated Small Cell Lung Cancer
ItalyVolrustomig in Patients with Unresectable Pleural Mesothelioma and Esophageal Squamous Cell Carcinoma
ItalyA study to compare glofitamab against a drug combination for patients with relapsed or refractory mantle cell lymphoma
ItalyTesting MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment
ItalyA Study Comparing PF-08046054 to Docetaxel in Adults with Previously Treated PD-L1 Positive Non-Small Cell Lung Cancer
ItalyA study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation
ItalyA study comparing erdafitinib delivery system to chemotherapy for patients with high-risk non-muscle-invasive bladder cancer who received BCG treatment
ItalyStudy comparing GSK5764227 and topotecan in adults with relapsed small cell lung cancer
ItalyGet verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
